Combination Cancer Immunotherapy of Nanoparticle-Based Immunogenic Cell Death Inducers and Immune Checkpoint Inhibitors

Jing Qi, Feiyang Jin, Xiaoling Xu, Yongzhong Du Institute of Pharmaceutics, College of Pharmaceutical Sciences, Zhejiang University, Hangzhou, 310058, People’s Republic of ChinaCorrespondence: Yongzhong Du 866 Yu-Hang-Tang Road, Hangzhou, 310058, People’s Republic of ChinaTel +86...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Qi J, Jin F, Xu X, Du Y
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2021
Materias:	tumor immunotherapy immunogenic cell death nanoparticles immune checkpoint inhibitors Medicine (General) R5-920
Acceso en línea:	https://doaj.org/article/afe7954862774a438c2db98a4a010640
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:afe7954862774a438c2db98a4a010640
record_format	dspace
spelling	oai:doaj.org-article:afe7954862774a438c2db98a4a0106402021-12-02T14:18:12ZCombination Cancer Immunotherapy of Nanoparticle-Based Immunogenic Cell Death Inducers and Immune Checkpoint Inhibitors1178-2013https://doaj.org/article/afe7954862774a438c2db98a4a0106402021-02-01T00:00:00Zhttps://www.dovepress.com/combination-cancer-immunotherapy-of-nanoparticle-based-immunogenic-cel-peer-reviewed-article-IJNhttps://doaj.org/toc/1178-2013Jing Qi, Feiyang Jin, Xiaoling Xu, Yongzhong Du Institute of Pharmaceutics, College of Pharmaceutical Sciences, Zhejiang University, Hangzhou, 310058, People’s Republic of ChinaCorrespondence: Yongzhong Du 866 Yu-Hang-Tang Road, Hangzhou, 310058, People’s Republic of ChinaTel +86-571-88208435Email duyongzhong@zju.edu.cnAbstract: Cancer immunotherapy is a promising treatment strategy that aims to strengthen immune responses against cancer. However, the low immunogenicity of tumor cells and inhibition of effector T cells in the tumor immunosuppressive microenvironment remain two major challenges. Immunogenic cell death (ICD) inducers not only directly kill cancer cells but also increase the tumor immunogenicity and induce antitumor immune responses. Immune checkpoint inhibitors can alleviate the inhibition of immune cells. Significantly, the combination of ICD inducers and immune checkpoint inhibitors elicits a remarkable antitumor effect. Nanoparticles confer the ability to modulate systemic biodistribution and achieve targeted accumulation of administered therapeutic agents, thereby facilitating the clinical translation of immunotherapies based on ICD inducers in a safe and effective manner. In this review, we summarize the nanoparticle-based chemical and physical cues that induce effective tumor ICD and elicit an antitumor immune response. In particular, combination of ICD inducers with immune checkpoint inhibitors can further reverse immunosuppression and prevent tumor metastasis and recurrence. An overview of the future challenges and prospects is also provided.Keywords: tumor immunotherapy, immunogenic cell death, nanoparticles, immune checkpoint inhibitorsQi JJin FXu XDu YDove Medical Pressarticletumor immunotherapyimmunogenic cell deathnanoparticlesimmune checkpoint inhibitorsMedicine (General)R5-920ENInternational Journal of Nanomedicine, Vol Volume 16, Pp 1435-1456 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	tumor immunotherapy immunogenic cell death nanoparticles immune checkpoint inhibitors Medicine (General) R5-920
spellingShingle	tumor immunotherapy immunogenic cell death nanoparticles immune checkpoint inhibitors Medicine (General) R5-920 Qi J Jin F Xu X Du Y Combination Cancer Immunotherapy of Nanoparticle-Based Immunogenic Cell Death Inducers and Immune Checkpoint Inhibitors
description	Jing Qi, Feiyang Jin, Xiaoling Xu, Yongzhong Du Institute of Pharmaceutics, College of Pharmaceutical Sciences, Zhejiang University, Hangzhou, 310058, People’s Republic of ChinaCorrespondence: Yongzhong Du 866 Yu-Hang-Tang Road, Hangzhou, 310058, People’s Republic of ChinaTel +86-571-88208435Email duyongzhong@zju.edu.cnAbstract: Cancer immunotherapy is a promising treatment strategy that aims to strengthen immune responses against cancer. However, the low immunogenicity of tumor cells and inhibition of effector T cells in the tumor immunosuppressive microenvironment remain two major challenges. Immunogenic cell death (ICD) inducers not only directly kill cancer cells but also increase the tumor immunogenicity and induce antitumor immune responses. Immune checkpoint inhibitors can alleviate the inhibition of immune cells. Significantly, the combination of ICD inducers and immune checkpoint inhibitors elicits a remarkable antitumor effect. Nanoparticles confer the ability to modulate systemic biodistribution and achieve targeted accumulation of administered therapeutic agents, thereby facilitating the clinical translation of immunotherapies based on ICD inducers in a safe and effective manner. In this review, we summarize the nanoparticle-based chemical and physical cues that induce effective tumor ICD and elicit an antitumor immune response. In particular, combination of ICD inducers with immune checkpoint inhibitors can further reverse immunosuppression and prevent tumor metastasis and recurrence. An overview of the future challenges and prospects is also provided.Keywords: tumor immunotherapy, immunogenic cell death, nanoparticles, immune checkpoint inhibitors
format	article
author	Qi J Jin F Xu X Du Y
author_facet	Qi J Jin F Xu X Du Y
author_sort	Qi J
title	Combination Cancer Immunotherapy of Nanoparticle-Based Immunogenic Cell Death Inducers and Immune Checkpoint Inhibitors
title_short	Combination Cancer Immunotherapy of Nanoparticle-Based Immunogenic Cell Death Inducers and Immune Checkpoint Inhibitors
title_full	Combination Cancer Immunotherapy of Nanoparticle-Based Immunogenic Cell Death Inducers and Immune Checkpoint Inhibitors
title_fullStr	Combination Cancer Immunotherapy of Nanoparticle-Based Immunogenic Cell Death Inducers and Immune Checkpoint Inhibitors
title_full_unstemmed	Combination Cancer Immunotherapy of Nanoparticle-Based Immunogenic Cell Death Inducers and Immune Checkpoint Inhibitors
title_sort	combination cancer immunotherapy of nanoparticle-based immunogenic cell death inducers and immune checkpoint inhibitors
publisher	Dove Medical Press
publishDate	2021
url	https://doaj.org/article/afe7954862774a438c2db98a4a010640
work_keys_str_mv	AT qij combinationcancerimmunotherapyofnanoparticlebasedimmunogeniccelldeathinducersandimmunecheckpointinhibitors AT jinf combinationcancerimmunotherapyofnanoparticlebasedimmunogeniccelldeathinducersandimmunecheckpointinhibitors AT xux combinationcancerimmunotherapyofnanoparticlebasedimmunogeniccelldeathinducersandimmunecheckpointinhibitors AT duy combinationcancerimmunotherapyofnanoparticlebasedimmunogeniccelldeathinducersandimmunecheckpointinhibitors
_version_	1718391626522427392

Combination Cancer Immunotherapy of Nanoparticle-Based Immunogenic Cell Death Inducers and Immune Checkpoint Inhibitors

Ejemplares similares